OSE Immunotherapeutics Eulerpool Ziņas

OSE Immunotherapeutics Eulerpool News

OSE Immunotherapeutics Akciju Ziņas

OSE Immunotherapeutics tiek uzmanīgi vēroti no žurnālistu un investoru puses visā pasaulē. Jaunākās OSE Immunotherapeutics ziņas mēs apkopojam šeit.

• 10. septembris ·

  Yahoo
  OSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Registration Study for Cancer Vaccine Tedopi® in Second-Line Non-Small Cell Lung Cancer
• 24. jūlijs ·

  Yahoo
  OSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative Colitis
• 4. jūlijs ·

  Yahoo
  Boehringer and OSE to advance cancer immunotherapy to clinics
• 3. jūlijs ·

  Yahoo
  Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371
• 1. jūlijs ·

  Yahoo
  OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’
• 24. jūnijs ·

  Yahoo
  OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies
• 20. jūnijs ·

  Yahoo
  OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders at the FOCIS Annual Meeting, San Francisco (June 18 – 21)
• 19. jūnijs ·

  Yahoo
  OSE Immunotherapeutics Reports on its 2024 General Shareholders’ Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company’s Growth
• 12. jūnijs ·

  Yahoo
  OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in Non-Small Cell Lung Cancer by Dr Stephen Liu and Prof Benjamin Besse
• 5. jūnijs ·

  Yahoo
  OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant